- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02933307
Continuous Monitoring on the General Ward
Continuous Monitoring of Vital Signs in Hospitalized Patients
Rationale: Monitoring patients' vital signs is done to detect clinical deterioration. For this, the MEWS, a scoring list comprising seven vital signs measured by nursing staff, is used. Although the MEWS provides relevant data on patients' health status, the interval measurements may not capture early deterioration of vital signs, especially during the night. As a result, unsafe situations may occur such as periods of low oxygen saturation and cardiac arrhythmias, which are known to complicate postoperative course. Besides, this way of measuring vital signs may be stressful for patients and disturbs patients' sleep. New technology such as ViSi Mobile and HealthPatch allows for remote continuous monitoring of vital signs using wearable devices transmitting relevant data to nurses and clinicians. With this, the investigators think that clinical deterioration may be detected in an early phase and reduce nurse work load and patient distress.
Objective: to investigate the feasibility of wearable devices on the general ward.
Study design: feasibility study.
Study population: adult patients hospitalized on the internal medicine ward and adult postoperative patients on the surgical ward.
Intervention: patients in the intervention groups will be randomized in one of the two groups. Patients in the group 1 will wear ViSi Mobile; patients in group 2 will wear the HealthPatch. Wearable devices will be worn for at least three days. Regular MEWS measurements take place at usual time points.
Main study parameters/endpoints: Evaluation with patient and care givers (primary outcome measure), MEWS calculations, time between alarm (continuous data) and next regular MEWS measurement (nurse), intervention by nurse after alarm, admission to ICU, complications, side effects of devices, STAI scores, and PCS scores will be documented.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will wear one device for at least three days. Devices can be uncomfortable by being heavy or the patches can start itching. More measurements by nurses can take place when indicated, for example after alarms. The participating patients will fill out the STAI on daily basis and the PCS on the last day of hospitalization. Both questionnaires will take a few minutes to complete. Patients could benefit from early detection of clinical deterioration and early corrective interventions or ICU admissions.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient is 18 years or older on the day the informed consent will be signed.
- Patient is hospitalized on the surgical or internal medicine ward.
- MEWS measurements are required at least three times a day.
- Patient is able to speak, read and understand the local language of the investigational site, is familiar with the procedures of the study, and agrees to participate in the study program by giving oral and written informed consent prior to screening evaluations.
Exclusion Criteria:
- Frequency of MEWS measurements is less than three times a day.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Control group
Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
|
|
|
Experimental: HealthPatch (Intervention)
Patients with HealthPatch and regular MEWS measurements
|
The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
|
|
Experimental: ViSi Mobile (Intervention)
Patients with ViSi Mobile and regular MEWS measurements
|
ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Expectations & experiences of patients
Periodo de tiempo: 2-3 days after informed consent
|
Interviews of 15-20 minutes with patients after 2-3 days wearing a device or control group
|
2-3 days after informed consent
|
|
Expectations & experiences of care givers
Periodo de tiempo: 1 year
|
Interviews with nurses of 15-20 minutes at the end of the study.
Estimated amount of 6 nurses
|
1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
MEWS scores based on continuous data and data measured by nurses
Periodo de tiempo: 3 times a day, up to three days.
|
3 times a day, up to three days.
|
|
|
Amount of alarms by HealthPatch or ViSi Mobile
Periodo de tiempo: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Time between alarm (continuous data) and next regular MEWS measurement (nurse)
Periodo de tiempo: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Amount of extra MEWS measurements by nurses due to alarms
Periodo de tiempo: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Admission to ICU (yes/no)
Periodo de tiempo: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Duration of ICU hospitalization in days
Periodo de tiempo: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Complications caused by disease or surgical procedure
Periodo de tiempo: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Adverse events caused by devices
Periodo de tiempo: during 2-3 days when the patient wears a device
|
E.g. Itch or redness
|
during 2-3 days when the patient wears a device
|
|
Technical failures of devices (artifacts: a period longer than 1 minute the device does not measure vital parameters)
Periodo de tiempo: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Outcomes of the State Trait Anxiety Inventory (STAI)
Periodo de tiempo: Once a day during the 2-3 days the patient participantes in this study
|
Once a day during the 2-3 days the patient participantes in this study
|
|
|
Outcomes of the Pain Catastrophizing Scale (PCS)
Periodo de tiempo: On day 2 or 3 when patients participates in the study
|
On day 2 or 3 when patients participates in the study
|
|
|
System usability Scale
Periodo de tiempo: 1 year
|
1 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Gender
Periodo de tiempo: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Age
Periodo de tiempo: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Diagnosis
Periodo de tiempo: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Performed surgical procedure
Periodo de tiempo: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Harry van Goor, MD, PhD, FRCS, Radboud University Medical Center
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias por sitio
- Adenocarcinoma
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Enfermedades del sistema endocrino
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias de glándulas endocrinas
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades pancreáticas
- Neoplasias ductales, lobulillares y medulares
- Neoplasias pancreáticas
- Carcinoma Ductal
- Neoplasias colorrectales
- Carcinoma Ductal Pancreático
Otros números de identificación del estudio
- HEEL-2015-03
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .